Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M. Tannir, Michael E. Hurwitz, Lily Tang et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 27
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O. Siefker‐Radtke, Nizar M. Tannir, Daniel C. Cho et al.|European Urology|2022Cited by 20
140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLCEnriqueta Felip, Apar Kishor Ganti, David R. Spigel et al.|Annals of Oncology|2021Cited by 1
83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10Arlene O. Siefker‐Radtke, Robert Huddart, Ute Hoch et al.|Annals of Oncology|2021Cited by 0